Bessemer Group Inc. boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 21,81

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight a

WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today th

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweig

The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options

PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs a

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market l

PTC Therapeutics (PTCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimi

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immun

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher th

WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced th

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible n

PTC intends to grant the initial purchasers an option to purchase, within a 13-day period beginning

– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity – – Offe

PTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 202

Jefferies analyst Faisal Khurshid upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and ra

PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcri

PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anc

PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 202

TD Cowen analyst Joseph Thome upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight a

PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus

PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $700.000 million-$800.000 million to

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.03) per share which beat the analyst

– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, suppo

PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefit

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohor

Jefferies analyst Faisal Khurshid downgrades PTC Therapeutics (NASDAQ:PTCT) from Buy to Hold and

PTC Therapeutics, Inc. (PTCT) stock closed lower following the withdrawal of its New Drug Applicatio

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is likely to report earnings for its f